ReviewFrontiers in immunology2022
Folate Receptor Beta for Macrophage Imaging in Rheumatoid Arthritis.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Folate receptor beta drives NLRP3 inflammasome activation and pyroptosis in macrophages independent of folate binding.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Advances in nanotechnology for the diagnosis and management of autoimmune diseases.Asian journal of pharmaceutical sciences · 2026Review
- Targeting macrophages in OA nanomedicine: Therapeutic opportunity or delivery delusion? A pragmatic reappraisal.Asian journal of pharmaceutical sciences · 2026Article
- Folate-modified liposomal celastrol for rheumatoid arthritis: therapeutic efficacy and modulation of ROS/NF-κB/COX-2-related inflammatory signaling.Frontiers in immunology · 2026Article
- Nanoparticle-enabled molecular imaging diagnosis of osteoarthritis.Materials today. Bio · 2025Review
- Pharmacokinetic and Pharmacodynamic Study of Folic Acid-Modified Chitosan-Stearic Acid Nanomicelles Loaded with Tetrandrine for Rheumatoid Arthritis.Pharmaceutics · 2025Article
- Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Advancements in Targeting Macrophage Senescence for Age-Associated Conditions.Aging and disease · 2024Review
- Folate Receptor β (FRβ) Expression on Myeloid Cells and the Impact of Reticuloendothelial System on Folate-Functionalized Nanoparticles' Biodistribution in Cancer.Molecular pharmaceutics · 2024Article
- Metabolic and molecular imaging in inflammatory arthritis.RMD open · 2024Review
- Macrophage-Targeting DNA Nanomaterials: A Future Direction of Biological Therapy.International journal of nanomedicine · 2024Review
- Combined ROS Sensitive Folate Receptor Targeted Micellar Formulations of Curcumin Effective Against Rheumatoid Arthritis in Rat Model.International journal of nanomedicine · 2024Article
- Naringenin ameliorates collagen-induced arthritis through activating AMPK-mediated autophagy in macrophages.Immunity, inflammation and disease · 2023Article
- On the origin of the functional versatility of macrophages.Frontiers in physiology · 2023Article
- Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems.Drug delivery · 2022Review
- Folate Receptor Beta Signaling in the Regulation of Macrophage Antimicrobial Immune Response: A Scoping Review.Biomedicine hubArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-invasive imaging modalities constitute an increasingly important tool in diagnostic and therapy response monitoring of patients with autoimmune diseases, including rheumatoid arthritis (RA). In particular, macrophage imaging with positron emission tomography (PET) using novel radiotracers based on differential expression of plasma membrane proteins and functioning of cellular processes may be suited for this. Over the past decade, selective expression of folate receptor β (FRβ), a glycosylphosphatidylinositol-anchored plasma membrane protein, on myeloid cells has emerged as an attractive target for macrophage imaging by exploiting the high binding affinity of folate-based PET tracers. This work discusses molecular, biochemical and functional properties of FRβ, describes the preclinical development of a folate-PET tracer and the evaluation of this tracer in a translational model of arthritis for diagnostics and therapy-response monitoring, and finally the first clinical application of the folate-PET tracer in RA patients with active disease. Consequently, folate-based PET tracers hold great promise for macrophage imaging in a variety of (chronic) inflammatory (autoimmune) diseases beyond RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.